Abbott Laboratories’ share price declined by approximately 9% in January following its Q4 earnings release, a move driven largely by market anxiety rather than operational weaknesses. Despite a revenue shortfall in its Nutrition and Diagnostics segments, the stock’s pullback has brought its valuation metrics—such as a forward price-to-earnings multiple near 28.9 and a dividend yield of roughly 2.3%—into historically attractive ranges. Long-term investors are viewing this correction as an entry point, citing ABT’s resilient cash flow generation, consistent buyback program and position within critical healthcare end markets.

In Q4, Abbott reported revenue of $11.46 billion, a 4.4% increase year-over-year but approximately 3% below consensus estimates. Adjusted earnings per share of $1.50 matched analyst expectations. Segment performance was uneven: Medical Devices revenue rose 12.3% to $5.68 billion, led by a 14.5% gain in Diabetes Care sales, while Nutrition sales fell 8.9% to $1.94 billion and Diagnostics dropped 2.5% to $2.46 billion. Management expanded adjusted operating margins by over 100 basis points and raised the quarterly dividend by 7%, marking ABT’s 50th consecutive year of annual dividend increases.

Abbott’s management issued 2026 full-year guidance of $5.55 to $5.80 in adjusted EPS and organic sales growth of 6.5% to 7.5%. The midpoint implies roughly 10% bottom-line growth year-over-year, exceeding consensus forecasts of about $5.17 per share. These targets incorporate continued investments in innovation—particularly in next-generation glucose monitoring and point-of-care diagnostics—as well as cost-saving initiatives designed to offset nutritional headwinds and evolving pandemic-related demand dynamics.

Twenty-two brokerages covering Abbott maintain an average recommendation of Moderate Buy, with seventeen buy ratings, two strong buy and three holds. Although several firms trimmed their 12-month price targets—Citigroup reducing from $155 to $140 and Sanford Bernstein from $154 to $125—most retained constructive outlooks, reflecting confidence in ABT’s long-term growth trajectory. Recent institutional buying by Vanguard and State Street, which increased stakes by 1.8% and 0.9% respectively in H2 2025, further underscores investor conviction in the company’s dividend growth and innovation pipeline.